Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Commercial plans.

When does this change take effect?

This change is effective Mar 4, 2026.

Back to dashboard

CommercialCoverageLow impact

08.02.32a, Afamitresgene autoleucel (Tecelra®)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Mar 4, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

This is a reissue of policy 08.02.32a for Afamitresgene autoleucel (Tecelra®), a specialized pharmacy treatment. The policy will be reissued effective March 4, 2026, with posting occurring March 5, 2026, affecting commercial insurance plans.

Action Required

Action needed

Before March 4, 2026: Review updated policy 08.02.32a for Afamitresgene autoleucel (Tecelra®) at the provided URL to understand any changes to coverage, prior authorization, or billing requirements for this specialized oncology treatment. This primarily affects practices that administer advanced cell therapies.

Related policy hubs

Independence Blue Cross policies Oncology Hematology